



PRESS RELEASE

Published: 2015-06-25; 08:00:00 CEST

***Stockholms Affärsänglar* (Stockholm Business Angels) and Almi Invest make capital investment in Inhalation Sciences AB (ISAB)**

STOCKHOLM, SWEDEN – June 25, 2015. **ISAB is broadening its ownership base: venture finance company *Stockholms Affärsänglar* (STOAF), together with Almi Invest, become new minority share owners, with a significant initial capital investment. The new ownership and investment reflects ISABs strategy of commercializing its world-leading technology platform for inhalation R&D.**

The capital investment, by *Stockholms Affärsänglar* (STOAF) and Almi Invest, is the first phase of a three-phase investment in ISAB. STOAF is a prestigious Swedish venture finance company and syndicate made up of angel investors. STOAF funds both young, innovative companies and multinationals that have unique skillsets in their field and strong market potential. Almi Invest is an industry-independent venture capital company and Sweden's most active investor in young growth companies. It focuses on companies with scalable business concepts and solid prospects for long-term capital growth.

Fredrik Sjövall, ISAB CEO: "We see increased possibilities from this broadening of our ownership base. Stockholm Business Angels' and Almi's expertise and network will help us realize and speed up the commercialization of our products following the first rollouts of our technology. Getting new owners onboard underlines the growing potential, scalability and exceptional technological caliber of our products."

STOAF CEO Klaus Gottwald: "With ISAB we have added another medtech venture to our portfolio of companies with a strong science and technology profile. STOAF will contribute to ISAB's development through new input in both funding and competence. With our strong international network of business contacts we look forward to helping ISAB establish itself in both Asia and the US."

Almi Invest Investment Manager Claes Post: "Thanks to Inhalation Sciences' technology platform the costs of developing treatments for a range of lung diseases can be significantly reduced. The consumption of expensive test substances during development can be minimized and the precision of the data generated dramatically improved. The pharmaceutical industry has a great need to reduce their development costs while still producing effective treatments against lung disease."

1

About Inhalation Sciences AB

Inhalation Sciences AB produces the world-leading inhalation R&D platform PreciseInhale. Uniquely versatile, PreciseInhale delivers data of a quality far beyond conventional inhalation R&D technologies. It has been embraced as a paradigm shift by many of the world's leading inhalation drug developers, research institutes, and universities. PreciseInhale speeds up drug development trials, enhances performance evaluation and moves clients closer to IVIVC. The platform is used extensively for Contract Research and is available for purchase and technology transfer to inhalation labs worldwide. Please visit inhalation.se

About Stockholms Affärsänglar

Stockholms Affärsänglar (STOAF) is one of Sweden's most prestigious and successful venture finance companies. STOAF focuses on ventures with strong market potential and entrepreneurs with active, unique skillsets in their field. STOAF syndicates with other angel investment and funding groups, including Almi Invest (Sweden's most active investor in young growth companies), as well as private angel investors. STOAF collaborates with *Connect Öst* (a nonprofit organization with a large network of business experts and investors) and SVCA (Swedish Private Equity & Venture Capital Association.) Please visit <http://www.stoaf.se/>

About Almi Invest

Almi Invest is Sweden's most active investor in young growth companies. Almi Invest is industry-independent and is made up of over 40 investment managers located across the whole of Sweden. With its broad regional presence and national coverage, the company reaches a broad spectrum of enterprises and brings together businesses and investors throughout Sweden, as well as a broad international network. Almi Invest's portfolio consists of 400 growth companies in a range of industries. Please visit: <http://www.almi.se/Almi-Invest/>

For further information, please contact:

Fredrik Sjövall, CEO
Fredrik.sjovall@inhalation.se
+46 (0)70 64 508 75